Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Transmolecular: Brain storm on cancer

Treatments for primary glioma rely on highly invasive surgeries and intensive radiation and chemotherapy. Recurrence after initial therapy is seen in about 98% of patients, and median survival after recurrence for high-grade gliomas is only two to four months. Further complicating the matter is that glioma-specific detection methods are invasive.
Transmolecular Inc. is opportunistically entering this space, based on a serendipitous discovery by co-founder Harald Sontheimer. In his lab at the University of Alabama, Sontheimer found the ion channel probe he

Read the full 805 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers